HUB Cyber Security Ltd. disclosed a 9.99% beneficial stake in Evofem Biosciences, Inc.’s common stock via a Schedule 13D. The filing dated Aug. 04, 2026 follows HUB’s June and July purchases of Evofem convertible notes and stock purchase rights paid with HUB equity. The position is capped at 9.99% and comes alongside a supplier-focused loan that gives HUB consent rights over major corporate moves.

Investor Intent

HUB says it made a strategic investment to strengthen its business and expand into women’s health and wellness, and it wants to work with Evofem. “HUB intends to explore opportunities to collaborate with the Issuer.” The new promissory note requires Evofem to get HUB’s consent before major actions like mergers, selling most assets, dissolving the company, changing its charter, or materially changing its business.

HUB may convert the notes or exercise purchase rights, but ownership limits cap it at 9.99% and Evofem’s share availability may also restrict actions. “HUB intends to review its investment on a continuing basis and may make suggestions or proposals concerning Evofem’s strategy, capital structure, and future plans,” including potential collaborations, financings, refinancings or restructurings of debt.

Investor's Background

HUB Cyber Security Ltd. is an Israel-based provider of confidential computing, AI-driven data fabric, and cybersecurity solutions, listed on Nasdaq under the symbol HUBC. The company focuses on protecting sensitive data and building secure infrastructure for enterprises and governments. HUB often uses strategic deals to bolster its balance sheet and enter adjacent markets that can benefit from its security technology.

Original SEC Filing: Evofem Biosciences, Inc. [ EVFM ] - SCHEDULE 13D - Aug. 04, 2026